```html

Zollinger‑Ellison Syndrome (Gastrin‑Producing Tumor)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (called gastrinomas) develop in the pancreas, duodenum, or the tissue surrounding the pancreas (the duodenopancreatic region). These tumors secrete excess gastrin, a hormone that normally stimulates the stomach to produce acid. When gastrin levels become abnormally high, the stomach releases far more acid than needed, leading to severe peptic ulcer disease, diarrhea, and malabsorption.

• Population affected: Most patients are adults aged 30‑60, but ZES can occur at any age, including childhood.
• Gender: Slight male predominance (≈55 % male, 45 % female).
• Prevalence: Approximately 1–3 cases per million people worldwide (Mayo Clinic, 2023). About 20‑25 % of cases are associated with a hereditary condition called multiple endocrine neoplasia type 1 (MEN‑1).

Symptoms

Because the excess acid affects the entire gastrointestinal (GI) tract, symptoms can be diverse. Not every patient experiences all of them.

Gastro‑intestinal symptoms

• Recurrent or refractory peptic ulcers – often multiple, located in the duodenum, jejunum, or even the esophagus.
• Severe epigastric burning pain that may improve with food or antacids but often returns.
• Chronic diarrhea – watery, sometimes greasy, due to acid‑induced inactivation of pancreatic enzymes.
• Steatorrhea (fatty stools) – a sign of malabsorption of fat‑soluble vitamins.
• Nausea & vomiting – especially after meals high in protein.

Systemic symptoms

• Weight loss despite normal or increased appetite.
• Fatigue – from anemia, nutrient deficiencies, or chronic disease burden.
• Heartburn or gastro‑esophageal reflux disease (GERD) – acid overload can reflux into the esophagus.
• Bone pain or fractures – long‑standing acid excess can cause secondary hyperparathyroidism and bone demineralization.

Symptoms suggestive of MEN‑1 association

• Hyperparathyroidism (high calcium, kidney stones).
• Pituitary tumors (headaches, visual changes, hormonal abnormalities).

Causes and Risk Factors

ZES is caused by the uncontrolled growth of gastrin‑secreting neuroendocrine cells. The underlying mechanisms differ between sporadic and hereditary forms.

Sporadic gastrinomas

• Arise spontaneously in the duodenum (≈70 %) or pancreas (≈25 %).
• Exact molecular triggers are not fully understood, but mutations in the MEN1 gene have been identified in up to 10 % of sporadic cases.

Hereditary (MEN‑1) associated gastrinomas

• MEN‑1 is an autosomal‑dominant syndrome caused by germline mutations of the MEN1 tumor‑suppressor gene.
• Patients with MEN‑1 have a 20‑30 % lifetime risk of developing gastrinomas.

Risk factors

• Family history of MEN‑1 or other endocrine tumors.
• Known genetic mutations in the MEN1 or CDKN1B genes.
• Previous history of pancreatic neuroendocrine tumors.

Diagnosis

Because the clinical presentation overlaps with common ulcer disease, a systematic approach is essential.

Initial evaluation

• Medical history & physical exam – focus on ulcer history, diarrhea, and signs of MEN‑1.
• Laboratory tests:
  • Fasting serum gastrin level – values > 1000 pg/mL are highly suggestive of ZES (normal < 100 pg/mL). Levels can be modestly elevated in other conditions (e.g., atrophic gastritis, proton‑pump inhibitor use), so the test is usually done after stopping PPIs for 7 days.
  • Secretin stimulation test – administration of secretin paradoxically raises gastrin in ZES (≥ 120 pg/mL rise).
  • Basic metabolic panel, calcium, vitamin D, and parathyroid hormone (PTH) to screen for MEN‑1.

Imaging studies

• Endoscopic ultrasound (EUS) – high‑resolution detection of small pancreatic or duodenal lesions.
• Multiphasic contrast‑enhanced CT or MRI – maps tumor size, vascular involvement, and metastatic spread.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – most sensitive for locating neuroendocrine tumors and metastases.

Pathology

If a lesion is resected, histology confirms a neuroendocrine tumor with immunohistochemical staining for gastrin.

Diagnostic criteria (summary)

1. Fasting gastrin > 1000 pg/mL (or > 10 × upper limit of normal) plus evidence of gastric acid hypersecretion, or
2. Fasting gastrin between 100–1000 pg/mL with a positive secretin stimulation test.
3. Imaging that localizes a gastrinoma (≥ 0.5 cm) or identifies metastatic disease.

Treatment Options

Management combines control of acid hypersecretion, eradication or reduction of the tumor, and long‑term surveillance.

Acid‑blocking therapy – first line

• Proton‑pump inhibitors (PPIs) (e.g., omeprazole 40‑80 mg daily, esomeprazole 40‑80 mg daily). PPIs are the most effective agents and are usually required lifelong.
• H2‑receptor antagonists (e.g., ranitidine, famotidine) may be added for breakthrough symptoms, but are less potent than PPIs.

Surgical management

• Curative resection – indicated when the tumor is localized and resectable (most duodenal gastrinomas). Options include:
  • Pancreaticoduodenectomy (Whipple) for pancreatic head lesions.
  • Enucleation or limited duodenal resection for small duodenal gastrinomas.
• Debulking surgery – removal of > 90 % of tumor burden when metastatic disease is present; improves symptom control but does not cure.
• Enucleation of metastatic liver lesions may be considered in selected patients.

Medical therapy for unresectable or metastatic disease

• Somatostatin analogues (octreotide, lanreotide) – suppress gastrin release and may shrink tumors.
• Targeted therapy – everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) have FDA approval for pancreatic neuroendocrine tumors and can stabilize disease.
• Chemotherapy – limited role; streptozocin‑based regimens are occasionally used for aggressive tumors.
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor–positive cells, showing promising response rates (NETTER‑1 trial).

Lifestyle & supportive measures

• Small, frequent meals low in fat to reduce acid stimulus.
• Avoid alcohol, caffeine, nicotine, and NSAIDs, which aggravate ulcer disease.
• Supplementation of fat‑soluble vitamins (A, D, E, K) and calcium/vitamin D if malabsorption is present.
• Regular bone density monitoring for osteoporosis.

Living with Zollinger‑Ellison Syndrome (gastrin‑producing tumor)

Long‑term management focuses on symptom control, nutrition, and surveillance.

Daily medication routine

• Take PPIs exactly as prescribed—usually once daily in the morning, with a second dose if nighttime symptoms occur.
• Set reminders for somatostatin analogue injections (monthly or weekly, depending on the product).
• Keep a medication list and share it with every healthcare provider.

Dietary tips

• Eat 5–6 small meals per day rather than three large ones.
• Choose low‑acid foods (bananas, oatmeal, lean proteins) and limit citrus, tomato‑based sauces, and spicy foods.
• Maintain adequate hydration; avoid carbonated drinks that increase gastric pressure.

Monitoring & follow‑up

• Serum gastrin levels every 6–12 months (or sooner if symptoms change).
• Annual imaging (EUS, CT/MRI, or 68Ga‑DOTATATE PET) to detect recurrence or metastasis.
• Bone density scan every 2–3 years if on long‑term PPIs or with low vitamin D.
• Screen for MEN‑1 manifestations: calcium/PTH annually, pituitary hormone panel if symptomatic.

Psychosocial aspects

• Join support groups (e.g., NET Patient Foundation) to share experiences.
• Consider counseling for anxiety/depression that can accompany chronic illness.
• Work with a dietitian experienced in neuroendocrine tumors for personalized nutrition plans.

Prevention

Because ZES is largely driven by genetic mutations, primary prevention is limited, but certain steps can reduce risk or facilitate early detection.

• Genetic counseling for families with known MEN‑1 mutations; cascade testing allows at‑risk relatives to undergo surveillance.
• Avoid chronic PPI overuse unless medically indicated—long‑term acid suppression can mask early ulcer symptoms, delaying diagnosis.
• Prompt evaluation of recurrent or atypical ulcers (especially if > 2 cm, multiple, or unresponsive to standard therapy) to rule out ZES early.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems.

• Severe, refractory peptic ulcers → perforation, bleeding, or obstruction.
• Gastrointestinal bleeding requiring transfusion or endoscopic intervention.
• Malabsorption & nutritional deficiencies (iron, vitamin B12, fat‑soluble vitamins) leading to anemia, neuropathy, and osteoporosis.
• Metastatic disease – up to 70 % of gastrinomas have liver metastases at diagnosis.
• MEN‑1–related tumors (parathyroid, pituitary) that add further morbidity.
• Secondary pancreatic insufficiency due to chronic acid injury.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Zollinger‑Ellison syndrome.” 2023; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). 2022; American College of Gastroenterology Guideline on Peptic Ulcer Disease 2022; WHO Classification of Tumours of the Digestive System 2020; Cleveland Clinic. “Neuroendocrine Tumors.” 2024; NIH Genetics Home Reference – MEN1. Peer‑reviewed studies: Moertel et al., NEJM 2021; Kulke et al., JCO 2022 (PRRT efficacy).

```